Tempest Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Tempest Therapeutics, Inc. (TPST) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2018-03-15
- Tempest Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2017 was $0.00.
- Tempest Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2016 was $0.00.
- Tempest Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2015 was $0.00.
- Tempest Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2014 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-15 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-15 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-15 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-02 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-16 |
| 2012-12-31 | $0.00 10-K · filed 2015-03-16 |
| 2011-12-31 | $0.00 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |